Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo

M.L.B. Hillaire; Martin van Eijk; S.E. Vogelzang-van Trierum; R.A.M. Fouchier; Ab Osterhaus; Henk Haagsman; G.F. Rimmelzwaan

doi:10.1016/j.virusres.2013.12.032

Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo

M.L.B. Hillaire, Martin van Eijk, S.E. Vogelzang-van Trierum, R.A.M. Fouchier, Ab Osterhaus, Henk Haagsman, G.F. Rimmelzwaan

Erasmus University Rotterdam

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Influenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resistant viruses. Antiviral drugs based on collectin-like surfactant protein D (SP-D) may fulfil these requirements. Especially porcine SP-D displays strong antiviral activity to influenza A viruses. In the present study the antiviral activity of recombinant porcine SP-D was investigated in ex vivo cultures of respiratory tract tissue infected with human influenza A virus of the H3N2 subtype. Porcine SP-D has antiviral activity in these test systems. It is suggested that porcine SP-D may be used as a venue to develop a novel class of antiviral drugs.

Original language	English
Pages (from-to)	22-26
Number of pages	5
Journal	Virus Research
Volume	181
DOIs	https://doi.org/10.1016/j.virusres.2013.12.032
Publication status	Published - 6 Mar 2014

Keywords

Porcine surfactant protein D
Influenza A virus
Antiviral activity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.virusres.2013.12.032

Embargoed Document

porcine
Final published version, 987 KB
Embargo ends: 1/01/50

Cite this

@article{f4680638f1e84c71a5bb38e7aa2d6bef,

title = "Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo",

abstract = "Influenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resistant viruses. Antiviral drugs based on collectin-like surfactant protein D (SP-D) may fulfil these requirements. Especially porcine SP-D displays strong antiviral activity to influenza A viruses. In the present study the antiviral activity of recombinant porcine SP-D was investigated in ex vivo cultures of respiratory tract tissue infected with human influenza A virus of the H3N2 subtype. Porcine SP-D has antiviral activity in these test systems. It is suggested that porcine SP-D may be used as a venue to develop a novel class of antiviral drugs.",

keywords = "Porcine surfactant protein D, Influenza A virus, Antiviral activity",

author = "M.L.B. Hillaire and {van Eijk}, Martin and {Vogelzang-van Trierum}, S.E. and R.A.M. Fouchier and Ab Osterhaus and Henk Haagsman and G.F. Rimmelzwaan",

year = "2014",

month = mar,

day = "6",

doi = "10.1016/j.virusres.2013.12.032",

language = "English",

volume = "181",

pages = "22--26",

journal = "Virus Research",

issn = "0168-1702",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo

AU - Hillaire, M.L.B.

AU - van Eijk, Martin

AU - Vogelzang-van Trierum, S.E.

AU - Fouchier, R.A.M.

AU - Osterhaus, Ab

AU - Haagsman, Henk

AU - Rimmelzwaan, G.F.

PY - 2014/3/6

Y1 - 2014/3/6

N2 - Influenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resistant viruses. Antiviral drugs based on collectin-like surfactant protein D (SP-D) may fulfil these requirements. Especially porcine SP-D displays strong antiviral activity to influenza A viruses. In the present study the antiviral activity of recombinant porcine SP-D was investigated in ex vivo cultures of respiratory tract tissue infected with human influenza A virus of the H3N2 subtype. Porcine SP-D has antiviral activity in these test systems. It is suggested that porcine SP-D may be used as a venue to develop a novel class of antiviral drugs.

AB - Influenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resistant viruses. Antiviral drugs based on collectin-like surfactant protein D (SP-D) may fulfil these requirements. Especially porcine SP-D displays strong antiviral activity to influenza A viruses. In the present study the antiviral activity of recombinant porcine SP-D was investigated in ex vivo cultures of respiratory tract tissue infected with human influenza A virus of the H3N2 subtype. Porcine SP-D has antiviral activity in these test systems. It is suggested that porcine SP-D may be used as a venue to develop a novel class of antiviral drugs.

KW - Porcine surfactant protein D

KW - Influenza A virus

KW - Antiviral activity

U2 - 10.1016/j.virusres.2013.12.032

DO - 10.1016/j.virusres.2013.12.032

M3 - Article

SN - 0168-1702

VL - 181

SP - 22

EP - 26

JO - Virus Research

JF - Virus Research

ER -

Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo

Abstract

Keywords

UN SDGs

Access to Document

Embargoed Document

Fingerprint

Cite this